Post Cardiac Arrest Syndrome (PCAS)- Market Insights, Epidemiology and Market Forecast- 2027

Albany, NY -- (SBWire) -- 12/18/2018 --DelveInsight has announced the addition of the "Post Cardiac Arrest Syndrome (PCAS)- Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Post-Cardiac Arrest Syndrome for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and Post-Cardiac Arrest Syndrome forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Request for sample pages

Following successful resuscitation from cardiac arrest, neurological impairment, as well as other types of organ dysfunction, still cause significant morbidity and mortality. The whole-body ischemia-reperfusion response that occurs during cardiac arrest and subsequent restoration of systemic circulation results in a series of pathophysiological processes that have been termed as the PCAS. The components of the PCAS comprise post-cardiac arrest brain injury, post-cardiac arrest myocardial dysfunction, the systemic ischemia-reperfusion response and persistent precipitating pathology. In another way, Cardiac Arrest (CA) is a major health and economic problem. The post-cardiac arrest period is segmented into four phases includes the immediate post-arrest phase, early post-arrest phase, intermediate phase and recovery phase.

DelveInsight estimates suggest that there were approx 1,150,165 diagnosed incident cases of sudden cardiac arrest in 2016 in 7 major markets. These diagnosed incident cases are further expected to increase by 2027. In 2016, 103,374 SCA cases have gained ROSC out of which 77,530 were ROSC-Comatose cases at the time of hospital admission in the United States. In 2016, the incident cases of IHSCA (In Hospital Sudden Cardiac Arrest) and OHSCA (Out of Hospital Sudden Cardiac Arrest) in Japan was found to be 72,117 and 123,000. These incident cases are further expected to increase by 2027. Among the European countries, Germany had the highest diagnosed incident cases of Sudden Cardiac Arrest with 148,438 cases, followed by the United Kingdom which had diagnosed incident cases of 77,400 in 2016. On the other hand, Spain had the lowest diagnosed incident cases of 30,000 cases in 2016.

Market analysis carried out for the period of 2016-2027 demonstrates that the Market size of Post-Cardiac Arrest Syndrome was found out to be USD 547.0 Million in 2016 in seven major markets for the forecasted period (2018-2027). The United States accounts for the largest market size of Post-Cardiac Arrest Syndrome, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

At present, there is no therapy approved for the treatment/prevention of PCAS and the current standard of neuroprotection is targeted temperature management and controlled Oxygenation. The current treatment approach has shown good results in many cases but still unable to reduce the mortality incidences. NeuroproteXeon/Mallinckrodt is developing Xenon gas as an add-on therapy with current standard of neuroprotectants to counter the post-cardiac arrest brain injury associated mortality. In the upcoming years, Xenex (Xenon gas + Delivery system) is anticipated to dominate the 2027 market of PCAS and is expected to hold decent market share.

Geography Covered
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Report Scope

The report covers a descriptive overview of the PCAS, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the PCAS and its treatment in the 7MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. Additionally, an all-inclusive account of both the current and emerging therapies for PCAS are provided, along with assessment of the impact new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted PCAS market is included in the report, covering drug outreach in 7MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global PCAS market.